FARMINGDALE, N.Y., May 16, 2016 /PRNewswire/ -- Misonix, Inc.
(NASDAQ: MSON), an international ultrasonic surgical device company
that designs, manufactures and markets innovative therapeutic
ultrasonic instruments for spine surgery, neurosurgery and other
surgical specialties, today announced that it will be exhibiting at
the 2016 SpineWeek conference in Singapore, to take place from May 16 to May 20, 2016.
Surgeon attendees at this important global conference from all
over the world will have the opportunity to trial the BoneScalpel,
and the newly launched minimally invasive spinal solution
BoneScalpel MIS, in a hands-on session at the exhibition.
Scott Ludecker, Senior Vice
President of Global Sales & Marketing, commented, "Advancements
like BoneScalpel MIS are enabling minimally invasive spine
procedures that have less post-operative pain, are safer, and
potentially return patients to their normal activities sooner than
otherwise possible with open procedures. Additionally, the
BoneScalpel MIS has been referred to as a 'game changer' by a
number of opinion leading surgeons and continues to gain acceptance
around the world. Participation in SpineWeek this year will serve
as a great forum for Misonix to continue its growth into the Asian
markets."
"SpineWeek 2016 in Singapore
represents a great opportunity for the team at Misonix to formally
introduce our newest surgical solutions to our expanding base of
surgeon customers already using BoneScalpel in this part of the
world. We will also have the opportunity to demonstrate the unique
clinical benefits of BoneScalpel to new customers in hands-on
sessions. Misonix recently reported worldwide revenues from
BoneScalpel increased 41% in our third quarter. We look forward to
continuing to build on this exciting growth with the addition of
new surgeon customers as a result of their hands-on experience at
SpineWeek." added Michael A. McManus
Jr., President and Chief Executive Officer of Misonix.
About
Misonix
Misonix, Inc. designs, develops, manufactures and markets
therapeutic ultrasonic medical devices. Misonix's therapeutic
ultrasonic platform is the basis for several innovative medical
technologies. Addressing a combined market estimated to be in
excess of $1.5 billion annually;
Misonix's proprietary ultrasonic medical devices are used in spine
surgery, neurosurgery, orthopedic surgery, wound debridement,
cosmetic surgery, laparoscopic surgery, and other surgical and
medical applications. Additional information is available on
the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of
historical information contained in this press release, content
herein may contain "forward looking statements" that are made
pursuant to the Safe Harbor Provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based on
management's current expectations and are subject to uncertainty
and changes in circumstances. Investors are cautioned that
forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements
made. These factors include general economic conditions, delays and
risks associated with the performance of contracts, risks
associated with international sales and currency fluctuations,
uncertainties as a result of research and development, acceptable
results from clinical studies, including publication of results and
patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new
products, potential acquisitions, consumer and industry acceptance,
litigation and/or court proceedings, including the timing and
monetary requirements of such activities, the timing of finding
strategic partners and implementing such relationships, regulatory
risks including approval of pending and/or contemplated 510(k)
filings, the ability to achieve and maintain profitability in the
Company's business lines, and other factors discussed in the
Company's Annual Report on Form 10-K, subsequent Quarterly Reports
on Form 10-Q and Current Reports on Form 8-K. The Company disclaims
any obligation to update its forward-looking
relationships.
Misonix
Contact:
|
Investor
Contact:
|
Richard
Zaremba
|
Joe Diaz & Lytham
Partners
|
631-694-9555
|
602-889-9700
|
invest@misonix.com
|
info@misonix.com
|
Logo - http://photos.prnewswire.com/prnh/20160201/328020LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/misonix-features-new-bonescalpel-mis-at-spineweek-2016-in-singapore-300269221.html
SOURCE Misonix, Inc.